Browsing Centre for Neuroscience, Surgery and Trauma by Title
Now showing items 128-147 of 1368
-
B Cells and EBV Infection in People with MS
(2009-03-17) -
Barriers and facilitators of weight bearing after hip fracture surgery among older adults. A scoping review.
(2023-07)PURPOSE: This scoping review aimed to synthesise the available evidence on barriers and facilitators of weight bearing after hip fracture surgery in older adults. METHODS: Published (Cochrane Central, MEDLINE, EMBASE, ... -
Baseline quality of life in people with hip fracture: results from the multicentre WHiTE cohort study
(2020-08-06)Aims To assess the variation in pre-fracture quality of life (QoL) within the UK hip fracture population, and quantify the nature and strength of associations between QoL and other routinely collected patient characteristics ... -
Becoming confident about confidence intervals
(British Editorial Society of Bone and Joint Surgery, 2017-05-01)A clear understanding of variability is at the heart of many of the articles published by the Bone and Joint Journal. The terms variability, dispersion, spread, distribution and variance amongst many others are used to ... -
The Benefits of Olanzapine in Palliating Symptoms
Olanzapine has become a major drug in the management of chemotherapy-induced nausea and vomiting as a prophylactic agent. In addition, a recent randomized trial has demonstrated its benefits in treating nausea and vomiting ... -
Bergamot essential oil and its constituent linalool, inhibit cholinergically-mediated contractions of human and rat isolated colon
(Wiley, 2019-08-19)Meeting Abstract 154 from NeuroGASTRO 2019 Congress, 5‐7 September 2019, Lisbon, Portugal -
Bilateral pulmonary metastasectomy through right thoracotomy.
(2013-07)Bilateral thoracotomies spaced at least 4 weeks apart are often required for the resection of bilateral pulmonary metastases. The anatomic distribution of the metastatic disease may rarely permit excision of bilateral ... -
Bone health, fracture risk, and Multiple Sclerosis: a UK Biobank study
(2020-04-14)Meeting abstract 3946 from Annual Meeting of the American-Academy-of-Neurology, Toronto, CANADA APR 25-MAY 01, 2020 -
Both cladribine and alemtuzumab may effect MS via B-cell depletion.
(2017-07)OBJECTIVE: To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies. ... -
Both cladribine and alemtuzumab may effect multiple sclerosis via B cell depletion
(Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology., 2017-06-05)